Humanin
Also known as: HN
Last updated: 1/23/2026 Last reviewed: 1/23/2026
At a Glance
Humanin is a mitochondrial-derived peptide described in early work as a “rescue factor” in experimental models of neuronal cell death relevant to familial Alzheimer’s disease genes and amyloid-beta–associated insults. [PMID: 11371646]
⚠️ Research Status: Humanin is not an approved medication. This page is educational and intentionally does not include protocols/dosing.
Mechanism of Action (TBD)
Mechanistic proposals include modulation of cell-death pathways in experimental settings; specific receptors/targets depend on the model and analog used. [PMID: 11371646]
Evidence Summary
Low Confidence In Vitro >10 YearsFoundational experimental work reported neuroprotection/rescue effects in model systems. [PMID: 11371646]
Safety & Unknowns
- Human clinical efficacy and safety are not established by experimental model evidence.
- Biology may differ between endogenous humanin and synthetic analogs used in studies.
Regulatory Status
| Region | Status |
|---|---|
| United States (FDA) | Not approved |
| European Union (EMA) | Not approved |
| WADA | Check current list (status may change) |
Changelog
| Date | Change |
|---|---|
| 2026-01-23 | Added dossier and linked primary literature |